Help funding trials for new multiple sclerosis treatment

Multiple Sclerosis (MS) is a disabling and degenerative disease of the nervous system which affects 2.3 million people worldwide and unfortunately continues to grow every year. The countries with the highest rate of patients affected by multiple sclerosis are the USA, Canada, the UK, Scandinavia and Australia.
Multiple Sclerosis causes progressive fatigue, muscle spasms and paralysis, incontinence, visual disturbances and other cognitive and neurological impairments. In the most severe cases, patients are unable to walk, speak, write or eventually breathe.

The disease affects people as early as 14 years old, although most sufferers start having symptoms at 30. It is a lifelong disease, which can deprive sufferers progressively from their jobs, their families and their friends. It affects twice as many women as men.

In the renowned Spanish Council for Research (CSIC) in Madrid, my research team has discovered a very promising molecule named VP 3.15. Early preclinical trials show that VP 3.15 has high therapeutic potential, better than the current treatments for multiple sclerosis which, at best – and not in all cases – are able to delay some of the symptoms of Multiple Sclerosis.

Help us to undertake the studies required to enter VP3.15 in clinical trials. We need to complete a number of studies in order to ensure the complete clinical development in a pharmaceutical company. Our objective is to cut the typical 15 year go-to-market period to less than 10 years, so we need your help!

Without YOUR help, we leave multiple sclerosis patients without a promising drug




music of the video from Antony Raijekov

in my lab

The goal

Turn a new treatment for people with multiple sclerosis into reality.

My name is Ana Martinez; I am a professor at the CSIC (public Spanish Institute of Research in Madrid, Spain) and one of the inventors of the molecule VP 3.15. I am so convinced of its effectiveness that I really want to pursue it´s clinical trials so it won’t be abandoned as a single identification number for way too long, as many promising molecules unfortunately are.

In order to make it real, together with my research team, I need US$ 90,000 (about €66,000) within the next two months, which will be put entirely towards achieving the preclinical phase assessing the proof of concept of the remyelination capacity of VP 3.15 (which corresponds to the ability of fixing damaged nerves).

Nevertheless, even though this first step would be an amazing achievement, I would like to stress that the second one, which costs US$300,000 (around €218,000) would allow us to develop a pharmaceutical form for clinical trials on humans and would therefore give GREAT HOPE to the success of this potential medication for patients with Multiple Sclerosis.

Of course, ALL DONATIONS will go directly to finance the research trials and NO PROFIT will be made.


Multiple Sclerosis: the details

Multiple Sclerosis (MS) is the most common, chronic, non-traumatic, central nervous system disabling disease affecting young adults. MS is diagnosed frequently between the ages of 20-40 years old. It is more frequent in women than in men (2:1 ratio which is moving closer to a 3:1 ratio according to the most recent reviews) and is characterized by the destruction of nerves’ insulation (myelin) resulting in the accumulation of irreversible disabilities.

MS is an extremely variable illness, ranging in severity from relatively benign to devastating. In the most severe cases, patients are unable to walk, speak or write.

You can find further information about MS on the website of the major patients association: the Multiple Sclerosis International Federation (


nervio afectado esclerosis multiple

Figure 2 Comparison between a normal nerve cell and a nerve cell affected by multiple sclerosis (


Hope for new treatment

Multiple Sclerosis has no cure. Today’s treatments help patients by reducing relapses and relieving symptoms. Their therapeutic objective is to decrease acute attacks and reduce the disease‘s progression.

What I discovered with molecule VP 3.15 goes further. Thanks to the inhibition of key enzymes in the development of the disease, molecule VP 3.15 has demonstrated high activity in all main components associated to MS: neuroprotection and remyelination, reducing inflammation and clinical symptoms, and preventing disease development. The product therefore has an ideal dual mechanism for the treatment of MS!

I have been working on this drug and its extremely promising benefits for more than 3 years now, but I don’t possess the funds to finance regulatory  preclinical trials. Thus, the release of this new medication is now not only dependent on the success of the upcoming trials, but first of all on raising the funds to conduct these trials.


Why GoFundMe?

In general it takes 15 years to bring a new drug into the market: too long for too many people. But together we can speed up the process by selectively funding critical phases at the very beginning. With your contribution we want to reduce the time needed to put the drug on the market.


Who am I?

I am  Research Professor at the Biological Research Centre (CIB) of Spanish National Council for Research (CSIC), with a background in Medicinal Chemistry.

In early 2014 I founded Ankar Pharma, a biotech startup whose goal is to fill the gap between basic drug discovery research and clinical trials needed for the effective pharmacological treatments of neurodegenerative diseases.

This molecule VP 3.15,  after renamed as AP-1, is the very first project that I am doing with Ankar Pharma and is the inspiration behind its creation.

Thank you very much for your help!